OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List

09 Apr 2018

• By Sten Stovall

Collaborating with the German family-controlled drug maker on OSE's novel checkpoint inhibitor aligns with French firm's strategy of partnering its portfolio candidates.

Laboratory — OSE and BI To Start OSE-172 Phase I Trials In Early 2019 • Source: Shutterstock

OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List

More from Strategy

More from Business